Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06000787 · ClinicalTrials.gov registry record · NA
MCT for the Harvard/UCSF ROBIN Center
A NA study of Neuroblastoma and Glioma, Childhood Brainstem, sponsored by Brigham and Women's Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 47
- Enrollment target
- 2
- Study locations
NCT06000787: Recruiting NA study of Neuroblastoma and Glioma, Childhood Brainstem, sponsored by Brigham and Women's Hospital.
NCT06000787 is a NA study of Neuroblastoma and Glioma, Childhood Brainstem that is actively recruiting participants, run by Brigham and Women's Hospital. The registered enrollment target is 47 participants, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (80% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06000787, a NA study of Neuroblastoma and Glioma, Childhood Brainstem, is actively recruiting participants, sponsored by Brigham and Women's Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 47 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of the Molecular Characterization Trial (MCT) is to obtain biological specimens and data resources from patients enrolled on prospective trials, to ensure that the Harvard/UCSF ROBIN Center accomplishes its key objective of advancing our understanding of the biological mechanisms that underlie how radiation treats tumors but also can cause unwanted side effects. The MCT focuses on collection of research biospecimens before, during, and after radiation. Also critical to the MCT is the deep annotation of these research biospecimens with elements that complement each other to provide a holistic, detailed view of each patient. Annotated elements include those used in the past such as clinical and biological features but extend to factors we have so far neglected but must incorporate in the future such as dosimetry (precise anatomical measurement of radiation dose), artificial intelligence, computational biology, and natural language processing.
Primary Outcome
EFS is calculated from the date of treatment assignment to the first episode of disease relapse or progression, second malignancy, or death, or until last contact if no event has occurred. This will be compared in participants with tumors showing high versus low tumor heterogeneity assessed quantitatively based on single-cell RNA sequencing.
Conditions Studied
Interventions
- RADIATION External beam radiotherapy
- RADIATION 131I-Metaiodobenzylguanidine (MIBG)
Study Locations (2)
California
- University of California, San Francisco - San Francisco
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2023-09-19 |
| Est. Completion | 2028-08-31 |
| Phase | NA |
What NCT06000787 shows while recruiting
NCT06000787 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 238-participant average among 94 other Neuroblastoma trials with a reported enrollment target (80% lower).
The record links to 2 conditions, with Neuroblastoma appearing as the primary indexed condition, and to 2 interventions - of which External beam radiotherapy is the first listed.
NCT06000787 reports a single indexed study location in California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06000787 about?
NCT06000787 is a clinical study titled "MCT for the Harvard/UCSF ROBIN Center". The goal of the Molecular Characterization Trial (MCT) is to obtain biological specimens and data resources from patients enrolled on prospective trials, to ensure that the Harvard/UCSF ROBIN Center accomplishes its key objective of advancing our understanding of the biological mechanisms that under...
What is the current status of trial NCT06000787?
This trial is currently recruiting. It is a NA study. The enrollment target is 47 participants. The study started on 2023-09-19. Estimated completion is 2028-08-31.
What conditions does trial NCT06000787 study?
This clinical trial studies the following conditions: Neuroblastoma, Glioma, Childhood Brainstem.
What interventions are being tested in trial NCT06000787?
The interventions under investigation include: External beam radiotherapy (RADIATION), 131I-Metaiodobenzylguanidine (MIBG) (RADIATION).
Who is sponsoring clinical trial NCT06000787?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06000787 being conducted?
This trial has 2 study locations across California, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06000787's enrollment target sits among peer trials
47 47th of 94 higher than 48 of 94 other Neuroblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuroblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
RECRUITING · NA
-
Phase II Study of Proton Radiation Therapy for Neuroblastoma
RECRUITING · NA
-
PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study
ACTIVE NOT RECRUITING · NA
-
Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma
COMPLETED · NA
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI